How Shareholders Can Take Advantage of Y-mAbs Therapeutics Stock Price Drop
April 13, 2023
Trending News 🌥️
Y-MABS ($NASDAQ:YMAB): Shareholders of Y-mAbs Therapeutics Inc. may be looking for ways to take advantage of the company’s stock price drop. Yesterday, the stock closed at $5.73, a -3.54% decrease from its closing price of $5.94 the day before. Y-mAbs Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of pediatric cancer and other life-threatening diseases. Investors who are looking to take advantage of the stock price drop could consider several strategies such as buying call options, selling put options, or using a collar strategy. Buying call options is an aggressive strategy in which investors purchase the right to buy the stock at a predetermined price at a later date.
Selling put options is a more conservative approach in which investors are paid to agree to buy a certain number of shares at a predetermined price on or before a specific date. Finally, a collar strategy combines buying a protective put option and selling a covered call option to protect against possible losses or missed opportunities. In conclusion, shareholders of Y-mAbs Therapeutics Inc. may be able to take advantage of the company’s stock price drop by considering different strategies such as buying call options, selling put options, or using a collar strategy. Investors should carefully consider their goals and risk tolerance before deciding which strategy to use.
Stock Price
On Monday, Y-MABS THERAPEUTICS opened at $5.8 and closed at $6.0, representing a rise of 5.6% from the previous closing price of 5.7. This could be an opportunity for shareholders to take advantage of the lower price and buy the stock. Given the company’s potential and track record of success, Y-mAbs Therapeutics Inc. shares may be a good long-term investment, with the current lower price providing a window of opportunity for investors to buy in at a reduced rate.
The company has been successful in researching and developing treatments for cancer, autoimmune diseases, and other rare diseases, and investors who believe in the company might be wise to capitalize on the current discount in stock price. Investors should do their due diligence and carefully consider their options before investing in Y-mAbs Therapeutics Inc., but the current discounted stock price could be a great opportunity for those looking for a long-term investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 65.27 | -95.57 | -146.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…
| Operations | Investing | Financing |
| -75.92 | 0 | 0.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 141.46 | 32.23 | 2.47 |
Key Ratios Snapshot
Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -145.3% |
| FCF Margin | ROE | ROA |
| -116.3% | -54.6% | -41.9% |
Analysis
GoodWhale has studied Y-MABS THERAPEUTICS and classified it as a ‘cheetah’, a type of company that has demonstrated high revenue or earnings growth but is considered less stable due to lower profitability. Through our analysis, we have identified that Y-MABS THERAPEUTICS is strong in asset and growth but weak in dividend and profitability. Additionally, we have assessed that it has an intermediate health score of 4/10, meaning it might be able to sustain future operations in times of crisis. This makes Y-MABS THERAPEUTICS an attractive investment opportunity for investors who understand the risk of investing in an unstable company but are willing to take on the potential rewards of a high-growth company. As such, these potential investors must be knowledgeable and understand the risks involved. Additionally, they should diversify their portfolio and invest in an array of companies with different levels of risk and reward. More…
Peers
The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.
– BioAtla Inc ($NASDAQ:BCAB)
BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).
– Adagio Therapeutics Inc ($NASDAQ:ADGI)
Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.
Summary
Investing in Y-mAbs Therapeutics Inc. can be a great opportunity for shareholders to beat the market. As of close of business last night, the stock price was at $5.73, down -3.54% from its previous closing price of $5.94.
However, the stock price moved up the same day, which suggests that the company may be undervalued. Analyzing the current market trends and news related to the company can help shareholders make informed decisions when investing in Y-mAbs Therapeutics Inc. Furthermore, investors should keep a close eye on the company’s financials and review any relevant developments that may affect their investment decisions. By doing this, they will be able to identify buying and selling opportunities and maximize their returns.
